Skip to main content

Table 4 The association between SUA and MetS, hypertension, central obesity, and CVD in women

From: The association between serum uric acid levels, metabolic syndrome and cardiovascular disease in middle aged and elderly Chinese: results from the DYSlipidemia International Study

 

SUA levels (μmol/L)

<230

230 ~ 270

270 ~ 310

310 ~ 360

>360

Q1

Q2

Q3

Q4

Q5

MetS ATP

Unadjusted

1(reference)

1.13 (0.97,1.33)

1.43 (1.23,1.66)

1.81 (1.55,2.11)

2.77 (2.39,3.21)

Model 1

1(reference)

1.13 (0.97,1.33)

1.43 (1.23,1.66)

1.81 (1.55,2.11)

2.77 (2.39,3.22)

Model 2

1(reference)

1.13 (0.97,1.32)

1.42 (1.22,1.65)

1.79 (1.54,2.09)

2.76 (2.38,3.21)

Model 3a

1(reference)

1.12 (0.96,1.32)

1.41 (1.21,1.64)

1.78 (1.53,2.08)

2.71 (2.34,3.16)

Model 41

1(reference)

1.08 (0.92,1.28)

1.31 (1.12,1.54)

1.62 (1.38,1.90)

2.35 (2.00,2.75)

MetS IDF

Unadjusted

1(reference)

1.01 (0.87,1.17)

1.22 (1.06,1.42)

1.41 (1.21,1.63)

2.05 (1.77,2.37)

Model 1

1(reference)

1.01 (0.87,1.18)

1.23 (1.06,1.42)

1.42 (1.22,1.65)

2.09 (1.80,2.42)

Model 2

1(reference)

1.00 (0.86,1.17)

1.22 (1.05,1.42)

1.40 (1.21,1.63)

2.08 (1.80,2.42)

Model 3a

1(reference)

1.00 (0.86,1.17)

1.21 (1.05,1.41)

1.40 (1.20,1.62)

2.06 (1.77,2.39)

Model 41

1(reference)

0.94 (0.80,1.10)

1.08 (0.92,1.26)

1.20 (1.02,1.41)

1.65 (1.41,1.94)

Central obesity

Unadjusted

1(reference)

1.06 (0.90,1.25)

1.19 (1.01,1.39)

1.26 (1.07,1.48)

1.50 (1.28,1.76)

Model 1

1(reference)

1.06 (0.91,1.25)

1.19 (1.02,1.40)

1.28 (1.08,1.50)

1.56 (1.33,1.83)

Model 2

1(reference)

1.06 (0.90,1.25)

1.19 (1.01,1.40)

1.27 (1.08,1.49)

1.56 (1.33,1.83)

Model 3b

1(reference)

1.06 (0.90,1.25)

1.18 (1.00,1.38)

1.24 (1.05,1.46)

1.49 (1.27,1.76)

Model 42

1(reference)

0.95 (0.80,1.14)

0.95 (0.80,1.14)

0.97 (0.80,1.16)

1.04 (0.86,1.25)

Hypertension

Unadjusted

1(reference)

1.11 (0.95,1.30)

1.38 (1.18,1.61)

1.75 (1.49,2.05)

2.37 (2.02,2.78)

Model 1

1(reference)

1.11 (0.95,1.30)

1.36 (1.16,1.59)

1.68 (1.43,1.98)

2.07 (1.76,2.44)

Model 2

1(reference)

1.10 (0.94,1.29)

1.35 (1.15,1.58)

1.67 (1.42,1.96)

2.06 (1.75,2.43)

Model 3c

1(reference)

1.10 (0.94,1.30)

1.36 (1.15,1.60)

1.65 (1.40,1.95)

1.97 (1.67,2.33)

Model 43

1(reference)

1.06 (0.89,1.25)

1.27 (1.08,1.50)

1.50 (1.26,1.79)

1.66 (1.39,1.98)

CHD

Unadjusted

1(reference)

1.12 (0.95,1.32)

1.22 (1.04,1.44)

1.38 (1.18,1.63)

1.68 (1.44,1.96)

Model 1

1(reference)

1.12 (0.95,1.33)

1.21 (1.02,1.43)

1.32 (1.02,1.43)

1.44 (1.23,1.67)

Model 2

1(reference)

1.12 (0.94,1.33)

1.20 (1.02,1.42)

1.31 (1.11,1.54)

1.42 (1.23,1.67)

Model 3d

1(reference)

1.10 (0.93,1.31)

1.15 (0.97,1.36)

1.22 (1.03,1.45)

1.30 (1.11,1.53)

Model 44

1(reference)

1.10 (0.92,1.31)

1.14 (0.96,1.36)

1.20 (1.01,1.42)

1.27 (1.07,1.50)

HF

Unadjusted

1(reference)

1.31 (0.85,2.04)

1.34 (0.87,2.06)

1.64 (1.08,2.47)

2.89 (1.99,4.21)

Model 1

1(reference)

1.33 (0.86,2.07)

1.33 (0.86,2.04)

1.54 (1.01,2.34)

2.31 (1.58,3.38)

Model 2

1(reference)

1.33 (0.85,2.07)

1.32 (0.85,2.04)

1.48 (0.97,2.26)

2.27 (1.55,3.33)

Model 3d

1(reference)

1.35 (0.87,2.11)

1.28 (0.83,1.98)

1.40 (0.92,2.14)

2.13 (1.45,3.12)

Model 44

1(reference)

1.32 (0.85,2.07)

1.22 (0.79,1.90)

1.31 (0.85,2.01)

1.91 (1.29,2.82)

PAD

Unadjusted

1(reference)

1.15 (0.44,3.00)

2.26 (0.99,5.19)

1.84 (0.78,4.36)

2.72 (1.23,6.02)

Model 1

1(reference)

1.15 (0.44,3.00)

2.24 (0.98,5.13)

1.77 (0.75,4.20)

2.42 (1.09,5.39)

Model 2

1(reference)

1.15 (0.44,3.00)

2.20 (0.96,5.05)

1.68 (0.71,3.99)

2.35 (1.05,5.24)

Model 3d

1(reference)

1.20 (0.46,3.13)

2.16 (0.94,4.97)

1.55 (0.65,3.70)

2.09 (0.93,4.68)

Model 44

1(reference)

1.16 (0.44,3.04)

2.10 (0.91,4.87)

1.59 (0.66,3.82)

2.07 (0.91,4.71)

  1. Model 1: adjusted for age
  2. Model 2: adjusted for variables included in model 1 and sedentary lifestyle, current smoke, alcohol consumption
  3. aModel 3: adjusted for variables included in model 2 and Family history of premature CVD, CHD, cerebrovascular disease, HF, PAD; b Model 3: adjusted for variables included in model 2 and Family history of premature CVD, CHD, cerebrovascular disease, HF, PAD, T2DM, hypertension; c Model 3: adjusted for variables included in model 2 and Family history of premature CVD, CHD, cerebrovascular disease, HF, PAD, T2DM; d Model 3: adjusted for variables included in model 2 and Family history of premature CVD, T2DM, hypertension
  4. 1 Model 4: adjusted for variables included in model 3a and BMI, TC, LDL-C, Diuretic agents use; 2 Model 4: adjusted for variables included in model 3b and BMI, TC, TG, HDL-C, LDL-C, Diuretic agents use; 3 Model 4: adjusted for variables included in model 3C and BMI, TC, TG, HDL-C, LDL-C, Diuretic agents use; 4 Model 4: adjusted for variables included in model 3C and WC, TC, TG, HDL-C, LDL-C, Diuretic agents use
  5. Abbreviations: SUA serum uric acid, MetS metabolic syndrome, CVD cardiovascular disease, ATP National Cholesterol Education Program Adult Treatment Panel III, IDF International Diabetes Federation, CHD coronary artery disease, TG triglyceride, TC total cholesterol, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol, T2DM type 2 diabetes mellitus, HF heart failure, PAD peripheral artery disease
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us